Topical vs Systemic Therapy in Psoriasis: Escalating Wisely in the Biologic Era

Introduction

Psoriasis is no longer viewed as a purely cutaneous disorder. It is a chronic immune-mediated disease that can involve the joints, carries a substantial psychosocial burden, and is clinically associated with cardiometabolic and inflammatory comorbidities. This broader understanding has appropriately changed treatment expectations.

The biologic era has further raised those expectations. Many patients with moderate-to-severe plaque psoriasis can now achieve near-clear or clear skin, and patients with psoriatic arthritis may benefit from systemic therapies that address both skin and musculoskeletal disease. At the same time, the expanding systemic armamentarium has created a more nuanced clinical question: are some patients being escalated before topical therapy has been thoughtfully optimized, while others remain undertreated because clinicians underestimate disease impact?

The most evidence-aligned approach is neither “topicals first” nor “biologics first,” but escalation with intent. Treatment intensity should match the patient’s total disease burden, not only the visible body surface area.

Why This Question Matters Now

Several developments have made this question timely. Randomized trials and systematic reviews have shown that biologics and targeted systemic agents are effective for moderate-to-severe plaque psoriasis. Severity definitions increasingly recognize that body surface area alone is insufficient. Psoriasis affecting the scalp, palms, soles, nails, genitals, or face may be disabling despite the limited surface area involved. Topical therapy itself has also improved, with newer nonsteroidal agents and better vehicles that may reduce corticosteroid exposure and improve treatment feasibility for selected patients.

The risk runs in both directions. Moving too quickly to biologics can burden some patients whose disease may be manageable with less intensive treatment. These patients may face additional costs, complex access requirements, screening, and long-term treatment challenges. Moving too slowly can result in persistent pain, itching, sleep disruption, work impairment, sexual dysfunction, stigma, or unrecognized psoriatic arthritis.

A practical framework should ask whether the patient has received the least burdensome therapy likely to meet the defined treatment target within a reasonable period.

Severity Is Treatment Candidacy, Not Just Body Surface Area

Body surface area remains useful, but it should not dominate treatment decisions. A patient with 3% involvement on the trunk may be well managed with topical therapy. A patient with 3% involvement of the palms, soles, genitals, scalp, or nails may require a broader evaluation because the functional and psychosocial impact may be much greater.

The International Psoriasis Council supports a treatment-candidacy approach. Patients may be considered candidates for systemic therapy if any of the following apply:

• Body surface area is greater than 10%.

• High-impact sites are involved.

• Topical therapy has failed.

National Psoriasis Foundation treatment targets have similarly encouraged clinicians to reassess treatment response rather than continue vague, open-ended therapy.

Table 1. Practical Severity-to-Treatment Framework

Clinical scenario	Usual starting point	Escalation trigger	Clinical nuance
Limited plaques, low symptom burden	Optimized topical therapy	Target not met after an adequate trial	Confirm diagnosis, vehicle fit, cost, and adherence
Scalp, face, genitals, hands, feet, or nails	Site-specific topical therapy or systemic treatment discussion	Functional, sexual, occupational, or quality-of-life impairment	Low BSA can still represent high-severity disease
BSA about 10% or higher	Phototherapy or systemic therapy	Persistent activity despite treatment	Avoid prolonged topical-only management
Suspected psoriatic arthritis	Rheumatology or coordinated systemic evaluation	Joint pain, dactylitis, enthesitis, or inflammatory back pain	Topical therapies do not treat joint disease
Erythrodermic or generalized pustular presentation	Urgent specialist management	Any suspected presentation	Do not manage as routine plaque psoriasis

This framework helps prevent two common errors: escalating limited, low-impact disease without first optimizing topical therapy, and keeping high-impact or systemic disease in a topical-only pathway because the measured BSA appears modest.

Topical Therapy Remains Foundational

Topical therapy is not a minor intervention. For many patients with limited plaque psoriasis, it remains the most appropriate first-line strategy. It is also frequently used alongside phototherapy, oral systemic therapy, or biologics.

The clinical failure of topical therapy should not be assumed until the regimen has been practical for the patient to use. A reasonable topical plan accounts for lesion location, potency, vehicle, frequency, affordability, patient dexterity, cosmetic acceptability, and maintenance. A twice-daily greasy ointment for scalp psoriasis is not an optimized regimen merely because the active ingredient is theoretically effective.

Topical corticosteroids are effective for rapid plaque control. However, their toxicity varies with potency, treatment area, duration, occlusion, and patient age. Thin skin, intertriginous areas, and genital involvement generally require lower-potency or steroid-sparing approaches. Vitamin D analogs and fixed corticosteroid-vitamin D combinations can reduce corticosteroid exposure and support maintenance. Calcineurin inhibitors are commonly used off-label for facial, inverse, or genital psoriasis, where corticosteroid toxicity is a particular concern.

Newer nonsteroidal agents have broadened topical treatment options. Tapinarof cream is an aryl hydrocarbon receptor agonist indicated for the topical treatment of plaque psoriasis in adults. Roflumilast cream is a topical phosphodiesterase-4 inhibitor indicated for plaque psoriasis, including intertriginous areas, in adults and pediatric patients 6 years and older. Roflumilast foam is indicated for plaque psoriasis of the scalp and body in adults and pediatric patients 12 years and older. These options may be useful when corticosteroid avoidance is desired, sensitive areas are affected, or ongoing treatment is needed.

Table 2. Topical Options in Plaque Psoriasis

Option	Typical role	Key safety issues	Clinical nuance
Topical corticosteroids	Rapid plaque control	Atrophy, striae, telangiectasia, and systemic absorption with extensive or prolonged use	Match potency to site and duration
Vitamin D analogs or combinations	Corticosteroid-sparing therapy and maintenance	Irritation; hypercalcemia is uncommon but possible with extensive use	Useful for chronic plaque control
Calcineurin inhibitors	Face, inverse, or genital areas	Burning or irritation	Commonly used off-label in psoriasis
Tapinarof cream	Nonsteroidal option for adult plaque psoriasis	Folliculitis, contact dermatitis, pruritus, headache, nasopharyngitis, and influenza	No corticosteroid-associated atrophy concern
Roflumilast cream or foam	Plaques, intertriginous areas, and formulation-specific scalp or body use	Contraindicated in moderate-to-severe hepatic impairment; gastrointestinal and application-site effects may occur; the foam is flammable during and immediately after application	Vehicle selection is clinically important; review relevant CYP3A4 and CYP1A2 interactions

Topical therapy becomes inappropriate when the disease burden exceeds what a feasible topical regimen can control. Repeated substitution among topical agents without a defined target can create the appearance of active management while delaying more effective therapy.

When Topical Therapy Is Not Enough

Systemic therapy should be considered when psoriasis is extensive, substantially affects daily life, recurs frequently, does not respond to optimized topical therapy, or is associated with suspected psoriatic arthritis.

Phototherapy may be appropriate for selected patients, particularly those with widespread stable plaque disease who prefer to avoid systemic drugs or have contraindications to systemic therapy. Access, travel burden, cumulative ultraviolet exposure, photosensitizing medications, and skin cancer history should be considered.

Clinicians should distinguish among three types of topical “failure.” Pharmacologic failure occurs when an appropriate topical therapy is used correctly but does not achieve the treatment goal. Implementation failure occurs when the regimen is too complex, cosmetically unacceptable, unaffordable, impractical, or poorly explained. Access failure occurs when the patient cannot obtain the medication or appropriate follow-up. Only pharmacologic failure necessarily indicates that the topical mechanism is inadequate, but all three situations require a change in strategy.

The escalation discussion should be explicit. A patient with persistent plaques over a large BSA, painful palmoplantar disease, genital psoriasis, severe scalp involvement, nail disease, or uncontrolled pruritus should not remain in indefinite topical cycling. The goal is not merely improvement, but disease control that matters to the patient and is measurable to the clinician.

Biologics and Targeted Oral Therapy: Highly Effective, Not Automatic

Biologics have changed the outcomes clinicians can expect in moderate-to-severe plaque psoriasis. TNF inhibitors, IL-17 inhibitors, IL-23 inhibitors, IL-12/23 inhibition, and newer targeted agents can produce substantial skin clearance in appropriate patients. Living network meta-analyses generally show that several biologics rank among the most effective therapies for achieving high levels of skin response during induction.

That evidence should be interpreted carefully. Network meta-analyses rely heavily on indirect comparisons, trial populations are selected, follow-up is often short- to medium-term, and long-term comparative safety is more difficult to establish than short-term efficacy. These limitations do not negate biologic efficacy. They argue against reflexive prescribing without a patient-specific rationale.

Targeted oral therapies have also complicated the older topical-versus-biologic binary. Apremilast, deucravacitinib, and icotrokinra occupy different mechanistic and safety spaces.

Deucravacitinib is a selective TYK2 inhibitor indicated for moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy and, under 2026 labeling, for active psoriatic arthritis in adults. Icotrokinra is an oral IL-23 receptor antagonist indicated for moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years and older who weigh at least 40 kg and are candidates for systemic therapy or phototherapy.

These agents provide systemic options that are not injectable biologics, but they still require label-specific patient selection, counseling, monitoring, and review of comorbidities and concomitant therapies.

Table 3. Systemic Therapy Considerations

Therapy category	Best fit	Key safety issues	Monitoring or limitation
Phototherapy	Widespread stable plaques; preference to avoid systemic drugs	Burns, phototoxicity, and cumulative exposure concerns	Access and visit burden can limit use
Methotrexate	Selected systemic plaque psoriasis; some PsA overlap	Hepatotoxicity, cytopenias, pulmonary toxicity, and teratogenicity	CBC, liver, and renal monitoring; dosing safety is critical
Cyclosporine	Severe or unstable disease requiring rapid control	Nephrotoxicity, hypertension, and drug interactions	Short-term use is generally favored; monitor blood pressure and renal function
Acitretin	Selected plaque, pustular, or keratinizing phenotypes	Teratogenicity, mucocutaneous effects, lipid abnormalities, and hepatotoxicity	Strict pregnancy avoidance; lipid and liver monitoring
Apremilast	Oral option when broad immunosuppression is less desirable	Gastrointestinal effects, weight decrease, depression warning, and hypersensitivity	Dose adjustment in severe renal impairment; avoid strong CYP450 enzyme inducers
Deucravacitinib	Oral targeted systemic option for adults	Hypersensitivity, infections, tuberculosis, malignancy including lymphoma, rhabdomyolysis or elevated CPK, triglyceride abnormalities, and liver enzyme abnormalities	Not recommended with other potent immunosuppressants or in severe hepatic impairment; avoid use in active tuberculosis
Icotrokinra	Oral IL-23 receptor-targeted option for eligible adults and adolescents	Clinically important active infection, tuberculosis considerations, live-vaccine avoidance, headache, nausea, cough, fungal infection, and fatigue	Monitor for adverse reactions when eGFR is below 60 mL/min/1.73 m²; no labeled contraindications
TNF inhibitors	Psoriasis with PsA or selected inflammatory comorbidities	Boxed warnings for serious infection and malignancy	Tuberculosis and infection screening; agent-specific cautions in selected comorbidities
IL-17 pathway inhibitors	High skin efficacy; some PsA utility	Infection, candidiasis, tuberculosis, inflammatory bowel disease concerns, and agent-specific warnings	Avoid class-wide assumptions; review each product’s labeling
IL-23 inhibitors	High skin efficacy and convenient dosing for many patients	Infection risk, tuberculosis evaluation, and live-vaccine avoidance	Onset, indication, monitoring, and comorbidity fit vary by agent

No table can replace current prescribing information. Before initiating systemic therapy, clinicians should verify current labeling, review vaccination status, evaluate infection risk, assess pregnancy potential, screen for psoriatic arthritis, consider drug interactions, and coordinate with rheumatology, gastroenterology, hepatology, nephrology, obstetrics, or other specialists when comorbidities affect drug selection.

Safety Requires Agent-Specific Thinking

Psoriasis therapies are frequently discussed by class, but safety considerations are not identical within a class.

TNF inhibitors carry boxed warnings for serious infections and malignancy. Patients require careful assessment for latent tuberculosis, serious active infection, and other infection risks. Clinical caution is also needed in selected patients with demyelinating disease, moderate-to-severe heart failure, chronic viral hepatitis risk, or a history of malignancy. The applicability and wording of individual warnings should be confirmed in the product-specific prescribing information.

IL-17 pathway agents are highly effective for skin disease but require attention to infection risk, including candidiasis and tuberculosis, as well as assessment for pre-existing or new or worsening inflammatory bowel disease. Secukinumab labeling includes warnings regarding inflammatory bowel disease. Brodalumab carries a boxed warning for suicidal ideation and behavior, is available through a REMS program, and is contraindicated in patients with Crohn’s disease. Bimekizumab labeling includes warnings for suicidal ideation and behavior, infections, tuberculosis, liver biochemical abnormalities, inflammatory bowel disease, and live vaccines.

IL-23 inhibitors also require agent-specific screening and counseling. Risankizumab labeling includes warnings and precautions involving infection risk, tuberculosis evaluation, and avoidance of live vaccines. For inflammatory bowel disease indications, label-specific liver testing considerations also apply. These distinctions matter because an agent selected for psoriasis may also be used or avoided because of coexisting Crohn’s disease, ulcerative colitis, or psoriatic arthritis.

Oral targeted agents should not be regarded as “simple” merely because they are administered orally. Apremilast labeling includes warnings and precautions for hypersensitivity, severe gastrointestinal symptoms, depression, and weight decrease. Strong CYP450 enzyme inducers may reduce apremilast exposure and result in loss of efficacy, and dosage adjustment is required in severe renal impairment.

Deucravacitinib labeling includes warnings and precautions involving hypersensitivity, infection, tuberculosis, malignancy including lymphoma, rhabdomyolysis and elevated creatine phosphokinase, laboratory abnormalities, immunizations, and potential risks related to JAK inhibition. The label notes that it is not known whether TYK2 inhibition is associated with the adverse reactions observed with JAK inhibition.

Icotrokinra labeling advises avoiding treatment initiation during a clinically important active infection, considering tuberculosis evaluation based on clinical judgment, and avoiding live vaccines. No dosage adjustment is recommended based solely on renal impairment, but the label advises monitoring for adverse reactions in patients with an eGFR below 60 mL/min/1.73 m² because systemic exposure may be increased.

These distinctions are clinically relevant for pharmacists and prescribers.

Psoriatic Arthritis: The Most Important Reason Not to Delay

Psoriatic arthritis is one of the clearest reasons to avoid prolonged topical-only management. The extent of skin disease does not reliably predict the severity of joint disease. Patients with limited plaques can still have synovitis, dactylitis, enthesitis, axial disease, or erosive disease.

Clinicians should routinely ask patients with psoriasis about morning stiffness, swollen joints, sausage digits, heel pain, inflammatory back pain, nail disease, and functional limitations. When psoriatic arthritis is suspected, rheumatology referral or coordinated dermatology-rheumatology care is appropriate. Topical therapy may improve skin lesions, but it does not treat systemic joint inflammation or prevent structural joint damage.

The presence of psoriatic arthritis also changes systemic treatment selection. Some therapies are stronger choices for skin disease, others for peripheral arthritis, others for axial disease, and others for coexisting inflammatory bowel disease. In this setting, interdisciplinary care can improve treatment selection and coordination.

Cardiometabolic Disease: Important, but Do Not Overstate Causality

Psoriasis is associated with obesity, metabolic syndrome, diabetes, dyslipidemia, hypertension, depression, smoking, alcohol use, and cardiovascular disease. These associations should inform overall care, but they should not be used to present dermatologic therapy as proven cardiovascular prevention.

Improvement in skin disease, systemic inflammatory markers, or surrogate imaging findings is not equivalent to a proven reduction in myocardial infarction, stroke, or cardiovascular mortality. Patients with psoriasis should receive standard evidence-based cardiovascular risk assessment and risk-factor management.

Dermatologic therapy should be selected for psoriasis control, joint protection when relevant, comorbidity fit, and patient-centered goals. It should not be framed as a substitute for lipid management, blood pressure control, smoking cessation, weight management, diabetes care, or other preventive interventions.

A Practical Escalation Approach

A useful clinical approach begins with five questions.

First, is the diagnosis correct? Mimics such as eczema, tinea, cutaneous lupus, seborrheic dermatitis, drug eruptions, pityriasis rubra pilaris, and cutaneous T-cell lymphoma can complicate management when the presentation or treatment response is atypical.

Second, how severe is the disease when measured by both extent and impact? BSA matters, but high-impact sites, symptoms, functional impairment, and quality of life may matter as much or more.

Third, has topical therapy been optimized? The regimen should be site appropriate, tolerable, affordable, and feasible. If the patient cannot realistically use it, it is not optimized.

Fourth, is systemic disease present? Joint symptoms, nail disease, severe recurrent flares, pustular disease, erythrodermic features, or substantial functional impairment should shift the discussion toward specialist evaluation and systemic therapy.

Fifth, what treatment target is being pursued? The target may include low residual BSA, scalp control, itch reduction, better sleep, ability to work, sexual comfort, improved hand function, or control of joint symptoms. A defined target prevents indefinite partial treatment.

For limited, low-impact plaques, optimized topical therapy with planned reassessment is appropriate. For high-impact disease, extensive involvement, topical treatment failure, or suspected psoriatic arthritis, phototherapy or systemic therapy should be discussed without unnecessary delay.

Are We Moving Too Fast to Biologics?

Sometimes, but the more common problem is imprecise escalation.

Biologics may be used too quickly when disease is limited, topical therapy has not been optimized, high-impact sites are not involved, psoriatic arthritis is not suspected, and the patient has not had a realistic trial of appropriate topical or phototherapy options. In that setting, escalation may reflect frustration, convenience, marketing pressure, payer dynamics, or clinician habit rather than disease necessity.

Biologics may be used too slowly when clinicians focus narrowly on BSA, underestimate genital or palmoplantar disease, miss psoriatic arthritis, or repeatedly prescribe short topical courses without a treat-to-target plan. In that setting, “conservative” care can become undertreatment.

The best approach is to identify the patient’s total disease burden, establish a treatment target, select the least burdensome therapy likely to meet that target, and reassess rather than defend topical or biologic therapy as a category.

Limitations of the Evidence

The evidence base is strong for the short- and medium-term skin efficacy of many topical, oral, and biologic therapies. It is weaker for long-term comparative safety, treatment sequencing, de-escalation, combination strategies, and outcomes in patients with multiple comorbidities.

Randomized trials may underrepresent older adults, patients with advanced kidney or liver disease, chronic infection risk, complex polypharmacy, pregnancy potential, severe obesity, or multiple immune-mediated diseases. Network meta-analyses help compare therapies across trial networks, but they are not a substitute for direct head-to-head trials or long-term registry data.

Real-world adherence also differs from trial adherence. A highly effective topical therapy may fail if the vehicle is unacceptable or the regimen is impractical. A biologic may be clinically appropriate yet inaccessible because of cost or payer restrictions. A systemic drug may be effective but poorly suited to a patient’s renal, hepatic, psychiatric, reproductive, or infection-risk profile.

Future Directions

Psoriasis treatment is moving toward greater individualization. Future practice will likely rely on improved biomarkers, comorbidity phenotyping, pragmatic head-to-head trials, longer-term comparative safety data, stronger evidence regarding pregnancy and lactation, and clearer treatment sequencing.

Topical treatment will also continue to evolve. Corticosteroid-sparing agents, scalp-friendly vehicles, intertriginous formulations, and practical maintenance regimens may reduce unnecessary escalation in selected patients. At the same time, more effective and convenient systemic options may reduce undertreatment in patients who have lived too long with uncontrolled disease.

The highest-value direction is a better match between treatment intensity and disease burden, safety, feasibility, and patient priorities, not simply more biologic or topical drugs.

References